Metabolism and Target Organ Damage

Call for Papers: Metabolic and Alcohol-Related Dual Liver Injury: Exploring MetALD

This Special Issue aims to explore the dual impact of these factors on liver health, specifically focusing on Metabolic Dysfunction and Alcohol-associated Liver Disease (MetALD).

Call for Papers: Metabolic Mysteries – The Role of Copper Dysregulation in Liver Disease

Guest Editors Prof. Ralf Weiskirchen and Prof. Wolfgang Stremmel have been named among the world’s top 2% of scientists for 2024!

A Special Interview with Prof. Matias A Avila, Newly Appointed Editorial Board Member of Metabolism and Target Organ Damage

Dr. Matias A Avila is a Professor of Biochemistry and Molecular Biology at the University of Navarra and Co-Director of the Solid Tumors Program at Cima.

Congratulations! Twenty-eight Editorial Board Members of Metabolism and Target Organ Damage Named among World’s Top 2% of Scientists for 2024!

This prestigious ranking identifies the top 2% of scientists globally from over 7 million scientists, spanning 22 fields and 174 sub-disciplines.

M&TOD Accepted for Inclusion in Emerging Sources Citation Index (ESCI) in June 2024

The journal will receive its first impact factor in June 2025, and all published papers will be comprehensively indexed in the Web of Science Core Collection.

Effect of cofactors on NAFLD/NASH and MAFLD - a paradigm illustrating the pathomechanics of organ dysfunction

Liver fibrosis in nonalcoholic fatty liver disease patients: noninvasive evaluation and correlation with cardiovascular disease and mortality

Concise review: gamma-glutamyl transferase - evolution from an indiscriminate liver test to a biomarker of cardiometabolic risk

Sarcopenia in the setting of nonalcoholic fatty liver

Metabolic primary liver cancer in adults: risk factors and pathogenic mechanisms

Pre-onlines

Post-transplant complications in alcohol and metabolic associated steatotic liver disease

Insulin increases type I collagen synthesis in hepatic stellate cells via α5β1 integrin

NAFLD to MAFLD: collaboration, not confusion - rethinking the naming of fatty liver disease

Articles

Most Recent | Most Viewed | Most Downloaded

Mouse models of primary sclerosing cholangitis: we just can't get enough

Maria Arechederra, ... Matias A. Avila

Open Access Commentary DOI: 10.20517/mtod.2024.106 4 Dec 2024

Views: Downloads:

Download PDF

Epigenetic and epitranscriptomic regulations of metabolic dysfunction-associated steatotic liver disease

Qiantao Zheng, Liangyou Rui

Open Access Review DOI: 10.20517/mtod.2024.75 2 Dec 2024

Views: Downloads:

Download PDF

A comprehensive review of patient-reported outcomes in metabolic dysfunction-associated steatotic liver disease

Aybuke Sapmaz, ... Zobair M. Younossi

Open Access Review DOI: 10.20517/mtod.2024.70 19 Nov 2024

Views: Downloads:

Download PDF

Liver fibrosis as a barometer of systemic health by gauging the risk of extrahepatic disease

Amedeo Lonardo

, ... Ralf Weiskirchen

Open Access Review DOI: 10.20517/mtod.2024.42 14 Nov 2024

Views: Downloads:

Download PDF

Metabolic dysfunction-associated steatotic liver disease: a key factor in hepatocellular carcinoma therapy response

Camilo Julio Llamoza-Torres

, ... Bruno Ramos-Molina

Open Access Review DOI: 10.20517/mtod.2024.64 12 Nov 2024

Views: Downloads:

Download PDF

Most Cited Papers In Last Two Years

Effect of cofactors on NAFLD/NASH and MAFLD - a paradigm illustrating the pathomechanics of organ dysfunction

Amedeo Lonardo

, ... Kusum K. Kharbanda

Open Access Perspective DOI: 10.20517/mtod.2022.14 21 Aug 2022

Views: Downloads:

Download PDF

Liver fibrosis in nonalcoholic fatty liver disease patients: noninvasive evaluation and correlation with cardiovascular disease and mortality

Stefano Ballestri

, ... Amedeo Lonardo

Open Access Review DOI: 10.20517/mtod.2022.23 30 Jan 2023

Views: Downloads:

Download PDF

Concise review: gamma-glutamyl transferase - evolution from an indiscriminate liver test to a biomarker of cardiometabolic risk

Amedeo Lonardo

, Gjin Ndrepepa

Open Access Review DOI: 10.20517/mtod.2022.20 29 Sep 2022

Views: Downloads:

Download PDF

Webinars

Ongoing Special Issues

Topic: Liver Fibrosis in Metabolic Dysfunction: Cellular and Molecular Mechanisms, Innovative Diagnostics, and Emerging Therapeutic Approaches

Assoc. Prof. Gyorgy Baffy; Prof. Amedeo Lonardo; Prof. Ralf Weiskirchen

Submission Deadline: 30 Jun 2025

Published articles: 5

Topic: Adipose Tissue and Metabolism in Chronic Diseases

Dr. Angelo Di Vincenzo; Prof. Marco Rossato

Submission Deadline: 15 Jun 2025

Published articles: 0

Editorial Board

Partners

Data

402

Authors

287

Reviewers

Articles

On Board Editors

2021

Published Since

For Authors

For Reviewers

Peer Review Guidelines

For Readers

Add your e-mail address to receive forthcoming Issues of this journal:

Topics Collection

Topic: Organ Dysfunction in Metabolic-Associated Fatty Liver Disease: Effect of Cofactors

Topic: Sex Differences in Dysmetabolic Organ Damage and Senescence

Topic: Hypogonadism in Cardiometabolic Disorders

Latest Issue

All Issues

Volume 4, Issue 4 (in progress)

Six Editorial Board Members of Metabolism and Target Organ Damage Featured on Clarivate’s “Highly Cited Researchers 2024” List

The Third Editorial Board Meeting of Metabolism and Target Organ Damage Held Successfully

Call for Papers: Metabolic and Alcohol-Related Dual Liver Injury: Exploring MetALD

This Special Issue aims to explore the dual impact of these factors on liver health, specifically focusing on Metabolic Dysfunction and Alcohol-associated Liver Disease (MetALD).

Call for Papers: Metabolic Mysteries – The Role of Copper Dysregulation in Liver Disease

Guest Editors Prof. Ralf Weiskirchen and Prof. Wolfgang Stremmel have been named among the world’s top 2% of scientists for 2024!

A Special Interview with Prof. Matias A Avila, Newly Appointed Editorial Board Member of Metabolism and Target Organ Damage

Dr. Matias A Avila is a Professor of Biochemistry and Molecular Biology at the University of Navarra and Co-Director of the Solid Tumors Program at Cima.

Congratulations! Twenty-eight Editorial Board Members of Metabolism and Target Organ Damage Named among World’s Top 2% of Scientists for 2024!

This prestigious ranking identifies the top 2% of scientists globally from over 7 million scientists, spanning 22 fields and 174 sub-disciplines.

M&TOD Accepted for Inclusion in Emerging Sources Citation Index (ESCI) in June 2024

The journal will receive its first impact factor in June 2025, and all published papers will be comprehensively indexed in the Web of Science Core Collection.

Effect of cofactors on NAFLD/NASH and MAFLD - a paradigm illustrating the pathomechanics of organ dysfunction

Liver fibrosis in nonalcoholic fatty liver disease patients: noninvasive evaluation and correlation with cardiovascular disease and mortality

Concise review: gamma-glutamyl transferase - evolution from an indiscriminate liver test to a biomarker of cardiometabolic risk

Topic: Liver Fibrosis in Metabolic Dysfunction: Cellular and Molecular Mechanisms, Innovative Diagnostics, and Emerging Therapeutic Approaches

Assoc. Prof. Gyorgy Baffy; Prof. Amedeo Lonardo; Prof. Ralf Weiskirchen

Submission Deadline: 30 Jun 2025

Published articles: 5

Topic: Adipose Tissue and Metabolism in Chronic Diseases

Dr. Angelo Di Vincenzo; Prof. Marco Rossato

Submission Deadline: 15 Jun 2025

Published articles: 0

News

Six Editorial Board Members of Metabolism and Target Organ Damage Featured on Clarivate’s “Highly Cited Researchers 2024” List

The Third Editorial Board Meeting of Metabolism and Target Organ Damage Held Successfully

Data

402

Authors

287

Reviewers

Articles

On Board Editors

2021

Published Since

Metabolism and Target Organ Damage

Effect of cofactors on NAFLD/NASH and MAFLD - a paradigm illustrating the pathomechanics of organ dysfunction

Liver fibrosis in nonalcoholic fatty liver disease patients: noninvasive evaluation and correlation with cardiovascular disease and mortality

Concise review: gamma-glutamyl transferase - evolution from an indiscriminate liver test to a biomarker of cardiometabolic risk

Sarcopenia in the setting of nonalcoholic fatty liver

Metabolic primary liver cancer in adults: risk factors and pathogenic mechanisms

Post-transplant complications in alcohol and metabolic associated steatotic liver disease

Insulin increases type I collagen synthesis in hepatic stellate cells via α5β1 integrin

NAFLD to MAFLD: collaboration, not confusion - rethinking the naming of fatty liver disease

Articles

Mouse models of primary sclerosing cholangitis: we just can't get enough

Epigenetic and epitranscriptomic regulations of metabolic dysfunction-associated steatotic liver disease

A comprehensive review of patient-reported outcomes in metabolic dysfunction-associated steatotic liver disease

Liver fibrosis as a barometer of systemic health by gauging the risk of extrahepatic disease

Metabolic dysfunction-associated steatotic liver disease: a key factor in hepatocellular carcinoma therapy response

Effect of cofactors on NAFLD/NASH and MAFLD - a paradigm illustrating the pathomechanics of organ dysfunction

Liver fibrosis in nonalcoholic fatty liver disease patients: noninvasive evaluation and correlation with cardiovascular disease and mortality

Concise review: gamma-glutamyl transferase - evolution from an indiscriminate liver test to a biomarker of cardiometabolic risk

Topic: Liver Fibrosis in Metabolic Dysfunction: Cellular and Molecular Mechanisms, Innovative Diagnostics, and Emerging Therapeutic Approaches

Topic: Adipose Tissue and Metabolism in Chronic Diseases

Effect of cofactors on NAFLD/NASH and MAFLD - a paradigm illustrating the pathomechanics of organ dysfunction

Liver fibrosis in nonalcoholic fatty liver disease patients: noninvasive evaluation and correlation with cardiovascular disease and mortality

Concise review: gamma-glutamyl transferase - evolution from an indiscriminate liver test to a biomarker of cardiometabolic risk

Sarcopenia in the setting of nonalcoholic fatty liver

Metabolic primary liver cancer in adults: risk factors and pathogenic mechanisms

Post-transplant complications in alcohol and metabolic associated steatotic liver disease

Insulin increases type I collagen synthesis in hepatic stellate cells via α5β1 integrin

NAFLD to MAFLD: collaboration, not confusion - rethinking the naming of fatty liver disease

Topic: Liver Fibrosis in Metabolic Dysfunction: Cellular and Molecular Mechanisms, Innovative Diagnostics, and Emerging Therapeutic Approaches

Topic: Adipose Tissue and Metabolism in Chronic Diseases

Six Editorial Board Members of Metabolism and Target Organ Damage Featured on Clarivate’s “Highly Cited Researchers 2024” List

The Third Editorial Board Meeting of Metabolism and Target Organ Damage Held Successfully

Committee on Publication Ethics

Portico

Committee on Publication Ethics

Portico